Business
CareDx Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,
About this update from Caredx, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it intends to offer and sell, subject to market and other conditions, up to $175.0 million of shares of its common stock in an underwritten public offering. CareDx also expects to grant the underwriters of the offering a 30 day option to purchase up to an additional $26.25 million of shares of its of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx. CareDx intends to use the net proceeds from this offering for working capital and general corporate purposes. Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Raymond James and Associates, Inc.; BTIG, LLC; Craig-Hallum Capital Group LLC and H.C. Wainwright & Co., LLC are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering. The public offering will be made pursuant to a shelf registration statement on Form S-3ASR (File No. 333-239049) previously filed with the Securities and Exchange Commission (the “SEC”) on June 9, 2020, which became effective immediately upon filing pursuant to SEC rules. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by e-mail at [email protected] or by telephone at (866) 471-2526; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at [email protected] or by telephone at (877) 821-7388. This press release does not constitute an ...